Elutia Inc. (ELUT) as of December 31, 2025 presents a materially changed balance sheet relative to year-end 2024, driven primarily by the October 2025 divestiture of its CIED Business to Boston Scientific for gross proceeds of approximately $80.4 million. The sale extinguished the company's SWK credit facility (repaid $23.1 million net) and the revenue interest obligation to Ligand, and generated a $80.2 million gain on disposal within discontinued operations. Post-divestiture, the surviving entity operates two small segments: Women's Health ($9.1 million 2025 net sales) and Cardiovascular ($3.2 million), with combined net sales of $12.3 million and segment gross profit of $7.7 million — insufficient to cover $26.9 million in operating losses from continuing operations. The company generated a GAAP net income of $53.4 million in 2025 entirely attributable to the divestiture gain. Under a liquidation lens, recovery to equity is constrained and marginal. Total reported assets are $62.4 million against total liabilities of $34.7 million, yielding book equity of $27.7 million; however, the MFFAIS CLV is estimated at only $7.6 million, reflecting aggressive haircuts to non-cash assets. Cash of $36.4 million is the dominant recoverable asset. Accounts receivable of $1.7 million (net of $0.5 million allowance) is thin and recoverable at approximately 90-95 cents. Inventory of $2.6 million carries a 60% haircut. PP&E net book value of $2.5 million (gross $2.8 million, minimally depreciated at $0.3 million) suggests recent capital investment; at 50-70% recovery the contribution is modest. Intangible assets net of $1.5 million are assigned zero recovery value. The liability side is the key constraint: current liabilities of $25.1 million include $11.2 million in LitigationReserveCurrent (FiberCel $6.8 million plus VBM $4.4 million), $4.8 million in accounts payable, and $4.4 million in accrued liabilities. Non-current liabilities include $3.6 million in operating lease obligations and $3.1 million warrant liability (fair-valued prefunded warrants classified as liabilities under ASC 815-40). The litigation reserve of $11.2 million is accrued at face and carried at face in liquidation — importantly, management states it is reasonably possible that losses could exceed the accrued amounts, with Medtronic counterclaim, Tiger litigation, and supplier litigation unquantified. The $4.8 million insurance receivable related to VBM litigation offsets a portion of the contingent liability but is a recoverable asset, not a netting. Operating lease commitments total $7.3 million undiscounted ($3.9 million PV, 12.1% discount rate) through post-2030, with the majority ($4.1 million) due after five years — these obligations do not extinguish on wind-up. The deferred tax asset of $37.8 million is fully reserved with a valuation allowance equal to the gross amount; zero book value carries to liquidation. Federal NOL carryforwards of $118.6 million (mostly indefinite life) have no liquidation value. The prior filing (Q3 2025 10-Q) disclosed a Nasdaq minimum bid price deficiency notice received November 7, 2025, with a compliance deadline of May 6, 2026. The 10-K does not include a subsequent update on compliance status. Filing discusses the revenue interest obligation extinguishment in connection with the CIED sale in MD&A but the RIO balance sheet line does not appear in TAG_CONTEXT for the current period, consistent with full payoff.
▼ Community Notes